Company intelligence / Profile preview
Biogen
Cambridge, Massachusetts, United Statesbiogen.com ↗
- Ownership
- Public · BIIB
- Employees
- ~9000
- Development stage
- Commercial
01
Overview
Biogen has a strong track record in neuroscience drug development with several commercialized therapies for MS and SMA. Its Alzheimer’s drug Aduhelm received FDA approval but has faced controversy over efficacy. The company continues to advance a broad pipeline targeting major neurological diseases.
- Therapeutic areas
- DermatologyImmunologyPsychiatryNeurology
- Modalities
- Small moleculesmonoclonal antibodies (mAbs)antisense oligonucleotidesbiosimilars
- Industry
- Pharma
02
Drug pipeline
100 assets99 more assets in the full pipeline.
Request access →03
Partnerships
Collaborations with Ionis Pharmaceuticals on antisense technologypartnerships with Eisai on Alzheimer’s therapiesother pharma/biotech alliances not detailed here but significant
04
Financials
- Market cap
- $31.8B
- Total revenue
- $2.7B
- Enterprise value
- $38.9B
Beyond the preview
Go deeper on Biogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biogen.